Patel Sushil
SEC CIK 1860609 · EDGAR
BoughtSold
Most active insiders at REPL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Patel Sushil | CEO, Dir | — | $811.2K |
| 2 | Hill Emily Luisa | CFO | — | $320.3K |
| 3 | Xynos Konstantinos | Chief Medical Off | — | $285.7K |
| 4 | Sarchi Christopher | Chief Commercial Off | — | $254.2K |
| 5 | Schwendenman Andrew | CAO | — | $139.1K |
| 6 | Astley-Sparke Philip | Dir | — | $89.7K |
| 7 | Dhingra Kapil | Dir | — | $33.0K |
Transactions 29
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 17:07 | 2026-08-10 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | S - Sale | $12.97 | -39.3K | 708.2K | -5% | -$510.3K | |
| DT | 2026-07-01 18:25 | 2026-06-29 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | M - OptEx | $37.54 | +2,955 | 27.2K | +12% | +$110.9K |
| DMT | 2026-07-01 18:25 | 2026-06-29 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $187.99 | -5,580 | 21.7K | -20% | -$1.05M |
| D | 2026-06-23 17:43 | 2026-06-18 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | A - Grant | $0.00 | +1,191 | 24.3K | +5% | $0 |
| 2026-05-20 16:15 | 2026-05-18 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | S - Sale | $5.08 | -37.3K | 747.5K | -5% | -$189.6K | |
| D | 2026-04-07 21:09 | 2026-04-01 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | A - Grant | $0.00 | +251.2K | 784.8K | +47% | $0 |
| 2025-12-19 | 2025-12-19 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | A - Grant | $0.00 | +200.0K | 533.6K | +60% | $0 | |
| 2025-12-04 | 2025-12-02 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | S - Sale | $11.13 | -10.0K | 333.6K | -3% | -$111.3K | |
| D | 2025-06-30 | 2025-06-26 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | A - Grant | $0.00 | +3,142 | 23.1K | +16% | $0 |
| 2025-05-22 | 2025-05-20 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | S - Sale | $8.06 | -25.1K | 343.6K | -7% | -$202.3K | |
| D | 2025-04-03 | 2025-04-01 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | A - Grant | $0.00 | +166.7K | 368.7K | +83% | $0 |
| 2024-12-18 | 2024-12-16 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | S - Sale | $12.42 | -10.0K | 202.0K | -5% | -$124.2K | |
| DT | 2024-11-04 | 2024-10-31 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | M - OptEx | $24.84 | +5,000 | 24.9K | +25% | +$124.2K |
| DT | 2024-11-04 | 2024-10-31 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $54.14 | -5,000 | 19.9K | -20% | -$270.7K |
| DT | 2024-07-10 | 2024-07-09 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $44.00 | -2,155 | 19.9K | -10% | -$94.8K |
| DT | 2024-07-10 | 2024-07-09 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | M - OptEx | $16.80 | +2,155 | 22.1K | +11% | +$36.2K |
| DA | 2024-06-28 | 2024-06-20 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | A - Grant | $0.00 | +4,248 | 19.9K | +27% | $0 |
| D | 2024-06-24 | 2024-06-20 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | A - Grant | $0.00 | +4,800 | 20.5K | +31% | $0 |
| 2024-05-20 | 2024-05-16 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | S - Sale | $6.47 | -20.2K | 212.0K | -9% | -$130.7K | |
| DT | 2024-04-12 | 2024-04-10 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | M - OptEx | $16.80 | +2,155 | 17.9K | +14% | +$36.2K |
| DT | 2024-04-12 | 2024-04-10 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $37.00 | -2,155 | 15.7K | -12% | -$79.7K |
| D | 2024-04-03 | 2024-04-01 | REPL | Replimune Group, Inc. | Patel Sushil | CEO, Dir | A - Grant | $0.00 | +83.3K | 232.2K | +56% | $0 |
| M | 2023-06-15 | 2023-06-13 | REPL | Replimune Group, Inc. | Patel Sushil | Chief Strategy Off | S - Sale | $24.04 | -5,698 | 148.9K | -4% | -$137.0K |
| D | 2023-06-12 | 2023-06-08 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | A - Grant | $0.00 | +5,200 | 15.7K | +50% | $0 |
| 2023-05-18 | 2023-05-16 | REPL | Replimune Group, Inc. | Patel Sushil | Chief Strategy Off | S - Sale | $18.05 | -15.6K | 154.6K | -9% | -$281.1K | |
| D | 2023-04-04 | 2023-04-01 | REPL | Replimune Group, Inc. | Patel Sushil | Chief Strategy Off | A - Grant | $0.00 | +40.0K | 170.1K | +31% | $0 |
| D | 2022-06-17 | 2022-06-16 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | A - Grant | $0.00 | +10.5K | 10.5K | New | $0 |
| 2022-05-18 | 2022-05-16 | REPL | Replimune Group, Inc. | Patel Sushil | Chief Commercial Off | S - Sale | $14.59 | -10.7K | 130.1K | -8% | -$155.9K | |
| D | 2022-04-05 | 2022-04-01 | REPL | Replimune Group, Inc. | Patel Sushil | Chief Commercial Off | A - Grant | $0.00 | +52.5K | 140.8K | +59% | $0 |
Purchase Sale Sale after option exercise All abbreviations